4SC Overview

  • Founded
  • 1997

Founded

  • Status
  • Public

  • Employees
  • 16

Employees

  • Stock Symbol
  • 0R6U

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $9.24
  • (As of Monday Closing)

4SC General Information

Description

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. It Geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

Contact Information

Website
www.4sc.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
LTS
Primary Office
  • Fraunhoferstr. 22
  • 82152 Planegg-Martinsried
  • Germany
+49 089 0000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

4SC Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.24 $9.59 $9.24 - $9.59 10.1M -$2.34

4SC Financials Summary

In Thousands,
USD 		TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
Revenue 406 458 16,681 2,567
EBITDA (7,577) (14,447) (10,381) (20,453)
Net Income (8,039) (15,099) (11,383) (21,645)
Total Assets 14,524 17,588 37,260 52,227
Total Debt 0 0 0 1,921
Public Fundamental Data provided by Morningstar, Inc. disclaimer

4SC Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 4SC‘s full profile, request access.

Request a free trial

4SC Patents

  • 458

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 16

    Granted

  • 4

    Pending

  • 000

    Expiring in next 12 mo

4SC Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019254578-A1 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment Inactive 17-Apr-2018 000000000
CA-3097087-A1 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment Pending 17-Apr-2018 000000000
EP-3781159-A1 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment Inactive 17-Apr-2018 000000000
US-20230201161-A1 Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment Pending 17-Apr-2018 000000000
AU-2019250696-A1 Pharmaceutical combination products comprising a histone deacetylase (hdac) inhibitor and a tlr7 agonist and/or tlr8 agonist for the treatment of cancer Inactive 14-Apr-2018 A61K31/4155
To view 4SC’s complete patent history, request access »

4SC Executive Team (11)

Name Title Board Seat Contact Info
Jason Loveridge Ph.D Chief Executive Officer & Chairman of the Management Board
Kathleen Masch-Wiest Chief Operating Officer & Board Member
Susanne Danhauser-Riedl MD Chief Medical Officer
Clemens Doppler Ph.D Chairman of the Supervisory Board
You’re viewing 4 of 11 executive team members. Get the full list »

4SC Board Members (10)

Name Representing Role Since
Clemens Doppler Ph.D Self Chairman of the Supervisory Board 000 0000
Helga Rubsamen-Schaeff Ph.D Self Member of the Supervisory Board 000 0000
Helmut Jeggle Self Supervisory Board Member 000 0000
Irina Antonijevic Ph.D Self Spervisory Board Member 000 0000
Jason Loveridge Ph.D 4SC Chief Executive Officer & Chairman of the Management Board 000 0000
You’re viewing 5 of 10 board members. Get the full list »

4SC Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

4SC Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore 4SC‘s full profile, request access.

Request a free trial

4SC Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 02-Nov-2015 0000 00000 00.000 Drug Discovery
Nexigen 26-May-2008 Corporate Drug Discovery
To view 4SC’s complete investments history, request access »

4SC ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view 4SC’s complete esg history, request access »

4SC Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 000000 02-Nov-2015 0000 00000 00.000 Completed
  • 4 buyers
Nexigen 26-May-2008 Corporate Completed
To view 4SC’s complete exits history, request access »